Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Advantan fatty ointment vasoconstriction dose-duration response study in healthy volunteers
ACTRN12623000272695Phase 4Completed
- Sponsor
- Zenith Technologies
- Start
- May 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of methylprednisolone aceponate in atopic dermatitis (AD) and psoriasis, sponsored by Zenith Technologies. Primary endpoints: ED50 parameter of Advantan fatty ointment, D1 parameter of Advantan fatty ointment and 1 more. Started May 2023; status: completed.
02
Drugs
methylprednisolone aceponate
03
Conditions
atopic dermatitis (AD)psoriasis
Beyond the preview
Go deeper on ACTRN12623000272695.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12623000272695.